KASIDY FLINK: Open Payments
NPI 1871248245 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$323 in 18 payments from 13 companies in 2025. Trend: 2023 $193 · 2024 $228 · 2025 $323
Food & beverage: $323
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $80 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $32 |
| Dexcom, Inc. | 1 | $22 |
| Ascensia Diabetes Care Us Inc. | 1 | $21 |
| AstraZeneca Pharmaceuticals LP | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Organon LLC | 1 | $16 |
| SANOFI-AVENTIS U.S. LLC | 1 | $15 |
Products named: Wegovy, CAPLYTA, JARDIANCE, Dexcom G6 Transmitter, Rybelsus, BREZTRI, Symbravo, REXULTI.
Industry payments across NE — which companies pay providers there.
